Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR181 a Novel Opioid Analgesic Molecule to Treat Chronic Pain

&160; SAN FRANCISCO Dec. 13 2011 PRNewswire &160;Nektar Therapeutics Nasdaq NKTR today announced positive data from a Phase 1 clinical study of NKTR181 evaluating multiple ascending oral doses of NKTR181 over an 8day treatment period in healthy ...